|Videos|August 22, 2016

Effects of Timing Conception to Avoid Congenital Zika Infection

Micaela Martinez, PhD, postdoctoral fellow in the Department of Ecology and Evolutionary Biology at Princeton University, explains the effects of timing conception to avoid congenital Zika infection.

Micaela Martinez, PhD, postdoctoral fellow in the Department of Ecology and Evolutionary Biology at Princeton University, explains the effects of timing conception to avoid congenital Zika infection.

Interview Transcript (slightly modified for readability)

“The socioeconomic implications of planning pregnancy seasonally [is] largely going to depend on how many people do this. If 3% of women plan their pregnancies to be timed with regard to Zika, that’s going to be very different than if 50% of pregnancies are timed.

I’m not a sociologist or an economist so I can’t speak too much to that, but one thing that I can say is that based on my work on measles and based on my work on polio, large changes in human demography, [or] birth rates, can have very far-reaching implications for the transmission of childhood diseases.

Even though we can plan pregnancy and [shift] when infants come into the population with the specific intent of protecting pregnant women from Zika, that could have implications for the transmission of other childhood diseases. That’s because if you think of the transmission of a childhood disease, having new births into a population [means] we have new susceptibles coming into the population.

Infants are like kindling for a forest fire; if the childhood disease epidemic is a forest fire, then fresh infants are that kindling. By shifting when births happen, and shifting when you have susceptibles coming in, that could change the transmission for other childhood infections, even though we are shifting those pregnancies to avoid Zika. So, we can see lots of downstream consequences of this; we just don’t know what they will be.”


Related to this article

Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.
Household Contacts Drive Most Hepatitis B Exposures in Young Children
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
Inhaled Amikacin Shows Low Resistance Rates in MAC Lung Disease in ENCORE
In the phase 3b ENCORE trial, adding amikacin liposome inhalation suspension (ALIS) to azithromycin and ethambutol significantly improved culture conversion in newly diagnosed MAC lung disease, while treatment-emergent amikacin (2.2%) and macrolide (1.1%) resistance stayed rare. Kevin Winthrop, MD, provides insights around the study.